Rakesh K. Jain, Ph.D.

Trustee, HQH, HQL (since 2007), THQ (since 2014) and THW (since 2015); Director, Steele Lab of Tumor Biology at Massachusetts General Hospital (since 1991); A.W. Cook Professor of Tumor Biology (Radiation Oncology) at Harvard Medical School (since 1991); Ad hoc Consultant/Scientific Advisory Board Member for pharmaceutical/biotech companies (various times since 2002); Ad hoc Consultant, Gershon Lehman Group (since 2004); Director, Co-Founder, XTuit Pharmaceuticals, Inc. (since 2011).

Thomas M. Kent, CPA

Trustee, HQH, HQL, THQ and THW (since 2017); Partner, PricewaterhouseCoopers LLP (1989-2013); Trustee, Principal Global Investors Trust Co. (since 2014); Trustee, Thayer Academy (since 2009); Trustee, New England Canada Business Council (since 2017).

Elizabeth G. Nabel, M.D.

Trustee, HQH, HQL, THQ and THW (since 2018); President, Brigham Health and Professor of Medicine at Harvard Medical School (since 2010); Director, Medtronic (since 2014); Director, Moderna, Inc. (since 2015); Member of the American Academy of the Arts and Sciences, the National Academy of Medicine, the Association of American Physicians and the American Society of Clinical Investigation; Fellow of the American Association for the Advancement of Science; serves on the boards of the Broad Institute, Ariadne Labs, and the Boys and Girls Club of Boston.

Daniel R. Omstead, Ph.D. *

Trustee, HQH, HQL (since 2003), THQ (since 2014) and THW (since 2015); President, HQH, HQL (since 2001), THQ (since 2014) and THW (since 2015); Chief Executive Officer and Managing Member, Tekla Capital Management LLC (since 2002); Director: GenomDx Biosciences Inc. (since 2016); IlluminOss Medical, Inc. (since 2012); Dynex Corporation (since 2012); Neurovance, Inc. (since 2015); EBI Life Sciences, Inc. (since 2015); Euthymics Biosciences, Inc. (since 2015); Veniti, Inc. (since 2015).

Oleg M. Pohotsky, MBA, J.D. 

Trustee, HQH, HQL (since 2000) THQ (since 2014) and THW (since 2015); Consultant and Managing Partner, Right Bank Partners (since 2002); Adviser, Board Advisers, Kaufman & Co. LLC (since 2008); Director, Avangard Investment Holdings (since 2010); Director, The New America High Income Fund, Inc. (since 2013).

William S. Reardon

Trustee, HQH, HQL (since 2010), THQ (since 2014) and THW (since 2015); Independent Consultant (since 2002); Director, Idera Pharmaceuticals, Inc (since 2019).

Lucinda H. Stebbins, CPA 

Trustee, HQH, HQL (since 2006), THQ (since 2014) and THW (since 2015); Independent Consultant, Deutsche Bank (2004-2015); Director, Bald Peak Land Company, Inc. (2008-2014); Director, Solstice Home Care, Inc. (since 2014).

* Trustee considered to be an “interested person” within the meaning of the Investment Company Act of 1940, as amended, through a position or affiliation with Tekla Capital Management LLC.